UDP-glucuronosyltransferase 1A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in Human Colon Cancer Cells

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Liu, Miao ^a   Wang, Qiong ^a   Liu, Fang ^a   Cheng, Xuefang ^a   Wu, Xiaolan ^a   Wang, Hong ^a   Wu, Mengqiu ^a   Ma, Ying ^a   Wang, Guangji ^a   Hao, Haiping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETICS, INTRAVENOUS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DITERPENES, ABIETANE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); PROPOFOL; REACTIVE OXYGEN SPECIES;

EID: 84893661785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079172     Document Type: Article

References (35)

1. Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40: 581-616. (Pubitemid 30340694)
2. Bushey RT, Dluzen DF, Lazarus P (2013) Importance of UDP- glucuronosyltransferases
3. 2 and 2A3 in tobacco carcinogen metabolism. Drug Metab Dispos 41: 170-179.
4. Cheng X, Liu F, Yan T, Zhou X, Wu L, et al. (2012) Metabolic Profile, Enzyme Kinetics, and Reaction Phenotyping of beta-Lapachone Metabolism in Human Liver and Intestine in Vitro. Mol Pharm 9: 3476-3486.
5. Tang Y, LeMaster DM, Nauwelaers G, Gu D, Langouet S, et al. (2012) UDP-glucuronosyltransferase-mediated metabolic activation of the tobacco carcinogen 2-amino-9H-pyrido[2,3-b]indole. J Biol Chem 287: 14960-14972.
6. Southwood HT, DeGraaf YC, Mackenzie PI, Miners JO, Burcham PC, et al. (2007) Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. Chem Res Toxicol 20: 1520-1527. (Pubitemid 350057222)
7. Desai AA, Innocenti F, Ratain MJ (2003) UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13: 517-523. (Pubitemid 37034594)
8. Nagar S, Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25: 1659-1672.
9. Cummings J (2003) Glucuronidation as a Mechanism of Intrinsic Drug Resistance in Human Colon Cancer: Reversal of Resistance by Food Additives. Cancer Res 63: 8443-8450.
10. Almagro MCd (2011) UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochemical Pharmacology 81: 60-70.
11. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29: 686-692. (Pubitemid 32374570)
12. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, et al. (2007) Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35: 2006-2014. (Pubitemid 350010805)
13. Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A (2008) Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 73: 611-620.
14. Strassburg CP, Manns MP, Tukey RH (1997) Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 57: 2979-2985. (Pubitemid 27315050)
15. Izumi K, Li Y, Ishiguro H, Zheng Y, Yao JL, et al. (2012) Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen. Mol Carcinog.
16. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36: 1461-1464.
17. Fu J, Huang H, Liu J, Pi R, Chen J, et al. (2007) Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 568: 213-221. (Pubitemid 46976900)
18. Han JY, Fan JY, Horie Y, Miura S, Cui DH, et al. (2008) Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 117: 280-295.
19. Jiang B, Zhang L, Wang Y, Li M, Wu W, et al. (2009) Tanshinone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin in vitro and in vivo. Food Chem Toxicol 47: 1538-1544.
20. Lu Q, Zhang P, Zhang X, Chen J (2009) Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer. Int J Mol Med 24: 773-780.
21. Wang J, Wang X, Jiang S, Yuan S, Lin P, et al. (2007) Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol 82: 11-21.
22. Zhang Z, Gao J, Wang Y, Song T, Zhang J, et al. (2009) Tanshinone IIA triggers p53 responses and apoptosis by RNA polymerase II upon DNA minor groove binding. Biochem Pharmacol 78: 1316-1322.
23. Su CC, Lin YH (2008) Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo. Int J Mol Med 22: 847-851.
24. Hao H, Wang G, Cui N, Li J, Xie L, et al. (2007) Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 8: 137-149. (Pubitemid 46218680)
25. Wang Q, Hao H, Zhu X, Yu G, Lai L, et al. (2010) Regioselective glucuronidation of tanshinone iia after quinone reduction: identification of human UDP-glucuronosyltransferases, species differences, and interaction potential. Drug Metab Dispos 38: 1132-1140.
26. Liu F, Yu G, Wang G, Liu H, Wu X, et al. (2012) An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer. PLoS ONE 7: e42138.
27. Hao H, Wang G, Cui N, Li J, Xie L, et al. (2006) Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med 72: 1311-1317. (Pubitemid 44862033)
28. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Miners JO (2007) The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos 35: 363-370. (Pubitemid 46333898)
29. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33: 139-146. (Pubitemid 40023525)
30. Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762.
31. Siegel D, Ross D (2000) Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29: 246-253.
32. Schlager JJ, Powis G (1990) Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45: 403-409. (Pubitemid 20087182)
33. Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW, et al. (2005) Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 43: 215-224. (Pubitemid 41134429)
34. Belinsky M, Jaiswal AK (1993) NAD(P)H:quinone oxidoreductase1 (DTdiaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12: 103-117. (Pubitemid 23220675)
35. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, et al. (2007) An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A 104: 11832-11837. (Pubitemid 47175098)